Shoulder Innovations
Shoulder Innovations' revenue rose 49.6% to $47 million in fiscal 2025. Its operating margin was −55.6%, down from −46.3% a year earlier. Free cash flow was −$36 million. The diluted share count rose 13340.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Shoulder Innovations does
Shoulder Innovations makes implants and related tools for shoulder replacement surgery. It focuses only on the shoulder. Its main products are InSet anatomic and reverse total shoulder replacement systems, where the replacement parts are designed to sit within the bone. Surgeons use them for patients whose shoulder pain comes from conditions such as arthritis, rotator cuff tears and fractures.
Revenue comes from selling these implant systems to hospitals and ambulatory surgery centers (ASCs), which are outpatient surgical facilities. It sells through its own commercial team and a network of independent distributors. It also offers ProVoyance, a planning tool that uses artificial intelligence to turn CT scans into 3D images so surgeons can plan an operation, and an instrument set that supports both main procedures with two trays. It says it competes in a very competitive business and that its sales depend on hospitals, ASCs, surgeons and patients adopting its products.
The company is early-stage and has a history of net losses. It has a loan agreement with Trinity, whose terms limit what it can do. As of December 31, 2025, it had 75 employees, 72 of them full-time.
Its biggest risks, as it describes them
- It has a history of net losses and may not reach or sustain profitability.
- It has a significant amount of debt, and its loan covenants may restrict how it operates.
- It may need more funding that is not available on acceptable terms.
- It faces competition, and sales depend on hospitals, surgery centers and surgeons adopting its implants.
- It relies partly on independent distributors to sell its products.
Income statement
Shoulder Innovations lost money in fiscal 2025: a net loss of $40 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 15 | 124 |
| Debt incl. finance leases | 15 | 15 |
| Net debt (negative means net cash) | −0 | −109 |
| Net debt to EBITDA | — | — |
| Debt to equity | — | 0.1x |
| Interest coverage | −11.1x | −375.7x |
| Current ratio | 4.6x | 11.1x |
| Quick ratio | 2.8x | 9.6x |
Cash flow
Projections
Project Shoulder Innovations' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $214,878 of Shoulder Innovations shares on the open market, and 3 insiders sold $5.5 million, $839,131 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Robert Joseph BallCEO & Executive Chairman, Director | Sold | 10,175 | $18.45 | $187,729 | Form 4 |
| Aug 26, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 1,196 | $22.60 | $27,030 | Form 4 |
| Aug 24, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 681 | $22.62 | $15,404 | Form 4 |
| Aug 21, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 20,516 | $22.61 | $463,867 | Form 4 |
| Aug 20, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 3,900 | $22.60 | $88,140 | Form 4 |
| Aug 18, 2026 | Matthew Fraser AhearnChief Operating Officer, Director | Sold plan | 14,186 | $20.99 | $297,759 | Form 4 |
| Aug 17, 2026 | Matthew Fraser AhearnChief Operating Officer, Director | Sold plan | 8,314 | $20.10 | $167,111 | Form 4 |
| Aug 6, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 2,095 | $22.60 | $47,347 | Form 4 |
| Aug 5, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 7,338 | $22.64 | $166,132 | Form 4 |
| Aug 4, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 99,812 | $22.77 | $2.3 million | Form 4 |
| Aug 3, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 10,751 | $22.71 | $244,155 | Form 4 |
| Jul 31, 2026 | Gilde Healthcare Holding B.V.10% owner | Sold | 20,034 | $22.73 | $455,373 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | −26.5% |
| Altman Z'' | 7.68 |
| Accruals ratio | −11.0% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Pass |
| Share count didn't rise | Fail |
| Gross margin rose | Fail |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Shoulder Innovations side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Shoulder Innovations | FY25 | 49.6% | −55.6% | −76.1% | — | — | — | |
| TriSalus Life Sciences | FY25 | 53.4% | −59.7% | −41.9% | — | — | 3 | Compare |
| Carlsmed | FY25 | 85.9% | −60.5% | −58.6% | — | — | — | Compare |
| SANUWAVE Health | FY25 | 35.0% | 11.2% | 4.4% | — | 1.7x | — | Compare |
| SS Innovations International | FY25 | 105.7% | −19.3% | −52.3% | — | — | — | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | 32 | 47 |
| Revenue growth | — | 49.6% |
| Gross profit | 24 | 36 |
| Research and development | 4 | 8 |
| Operating income | −15 | −26 |
| Net income | −16 | −40 |
| Diluted EPS (US$) | −242.04 | −4.65 |
| Diluted shares (millions) | 0 | 9 |
| Cash flow | ||
| Cash from operations | −14 | −29 |
| Capital expenditure | 4 | 7 |
| Free cash flow | −18 | −36 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 1 | 1 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 15 | 124 |
| Debt incl. finance leases | 15 | 15 |
| Total assets | 43 | 170 |
| Total liabilities | 23 | 29 |
| Shareholders' equity | −55 | 141 |
| Margins and ratios | ||
| Gross margin | 77.0% | 76.5% |
| Operating margin | −46.3% | −55.6% |
| Net margin | −49.4% | −85.3% |
| Free cash flow margin | −57.4% | −76.1% |
| Rule of 40 (growth + FCF margin) | — | −26.5% |
| Return on capital | — | — |
| Return on equity | — | −93.8% |
| Return on assets | — | −37.9% |
| Net debt to EBITDA | — | — |